论文部分内容阅读
目的 :探讨尿甘氨酰脯氨酸二肽氨基肽酶 (GPDA)诊断原发性高血压 (EH)早期肾损害的价值。方法 :采用本室建立的GPDA连续监测法 ,在OLYMPUSAU 2 70 0全自动生化分析仪上测定 77例EH患者和 72例正常人的尿液GPDA ,并与其他反映早期肾损害的N 乙酰 β D 氨基葡萄糖苷酶 (NAG)和尿微量白蛋白 (UmA)指标相比较。结果 :EH患者尿GPDA显著高于正常对照组 (P <0 .0 1) ,尿GPDA阳性检出率随病程延长而增高 ,尿GPDA与NAG和UmA呈正相关。结论 :尿GPDA测定作为一项新的诊断EH早期肾损害的参考指标 ,具有很好的临床应用价值
Objective: To investigate the value of urinary glycyl-proline dipeptidyl aminopeptidase (GPDA) in diagnosing early renal damage of essential hypertension (EH). Methods: GPDA continuous monitoring method established in our laboratory was used to determine the urinary GPDA of 77 EH patients and 72 normal persons on OLYMPUSAU 2 70 0 automatic biochemical analyzer. Glucosaminidase (NAG) and urinary microalbumin (UmA) indicators compared. Results: The urinary GPDA in patients with EH was significantly higher than that in controls (P <0.01). The positive rate of GPDA in urine was increased with the prolongation of the course of disease. The urinary GPDA was positively correlated with NAG and UmA. Conclusion: Urinary GPDA assay is a new reference value for diagnosis of early renal damage in EH and has good clinical value